The Ultimate Guide to Candida lusitaniae
A rare yeast that can develop resistance to last-resort treatment while you are being treated – making early identification critical.
Candida lusitaniae (also known as Clavispora lusitaniae) is a rare yeast species that accounts for a small fraction of all Candida infections. However, its clinical importance far outweighs its frequency because of a unique and dangerous characteristic: it can develop resistance to last-resort treatment during therapy.
Last-resort treatment is the therapy clinicians turn to when other options fail. When C. lusitaniae develops resistance to this therapy mid-treatment, the consequences can be severe – particularly in patients with weakened immune systems.
Why C. lusitaniae Matters
Resistance can emerge during treatment. Unlike species that are either resistant or susceptible from the start, C. lusitaniae can begin responding to treatment and then stop responding while you are still being treated. Early identification allows clinicians to choose alternative therapies proactively rather than discovering resistance after treatment has failed.
Symptoms
In the urinary tract, C. lusitaniae causes the same symptoms as other Candida species: burning during urination, needing to urinate frequently or urgently, and pelvic discomfort. It is most commonly seen in hospitalised patients with urinary catheters (tubes inserted into the bladder).
Who Is Most at Risk?
The most common setting for C. lusitaniae UTIs. Catheters provide a surface for the yeast to attach to and grow on.
Chemotherapy suppresses the immune system by reducing white blood cells (a condition called neutropenia), leaving patients vulnerable to rare fungal infections.
Prior treatment can select for resistant strains – surviving organisms are more likely to be the ones that can resist the treatment.
Neonates (newborn babies) in NICUs are particularly susceptible because their immune systems are not yet fully developed.
Rare but important to identify. Because C. lusitaniae is uncommon, it is often not considered when investigating a UTI. PCR testing identifies it alongside six other Candida species in a single panel, ensuring even uncommon causes are not missed.
C. lusitaniae in South Africa
Private Healthcare
Patients in private NICUs and adult ICUs are the most likely to encounter C. lusitaniae. South Africa's private hospital groups – Netcare, Mediclinic, and Life Healthcare – manage patients with indwelling devices and prolonged antifungal exposure, both of which are risk factors. The rarity of this species means it may not be considered in initial investigations, making PCR identification particularly valuable.
Public Healthcare
In tertiary public hospitals managing complex patients – burn units, transplant programmes, cancer wards – C. lusitaniae can emerge as an opportunistic infection (one that takes advantage of a weakened immune system). Limited access to advanced testing in the public sector means resistance may not be detected until treatment fails. A PCR result that identifies C. lusitaniae before treatment begins can prevent weeks of ineffective therapy.
Travellers and Foreign Nationals
Travellers are unlikely to encounter C. lusitaniae unless hospitalised during their stay. However, if you are a medical tourist undergoing a procedure in South Africa, or if you require emergency hospital admission, be aware that rare Candida species can establish themselves during any hospital stay. If you develop UTI symptoms after discharge, comprehensive PCR testing is more reliable than standard treatment based on guesswork.
Epicentre's UTI PCR Panel
UTI Package – 11-Target PCR Screen
Results in 5 – 7 working days · No doctor's referral needed · Walk-in or home kit available
Stop Guessing. Get Tested.
11-target UTI PCR panel. Walk in to any Epicentre branch – no doctor's referral needed – or order a home collection kit.
Frequently Asked Questions
What Is Candida lusitaniae?
How Is C. lusitaniae Diagnosed?
Why Is C. lusitaniae Dangerous?
Do I Need a Doctor's Referral?
References
- Hawkins, J.L. & Baddour, L.M. (2003). Candida lusitaniae infections in the era of widespread antifungal availability. Clinical Infectious Diseases, 36(2), e14 – e18.
